Ionis Director, Global HEOR, Rare Disease Immunology, Successfully Placed by The Chase Group
Director, Global HEOR Rare Disease Immunology reporting to Montserrat Vera-Llonch was filled for Ionis. This is a critical and significant role as the commercial function grows with the launch of one of the rare disease assets currently in Phase III. Montserrat’s team will lead development of global HEOR research strategies and plans. The Chase Group wishes the team much success in this strategic role! To learn more, email moira@chasegroup.com
Director, Global HEOR Rare Disease Immunology reporting to Montserrat Vera-Llonch was filled for Ionis. This is a critical and significant role as the commercial function…
The Chase Group is pleased to announce the successful completion of the Vice President, Medical Affairs search for Avidity Biosciences. Nathan Weedin brings 15+ years…
Ionis Pharmaceuticals has a 35-year track record of perfecting and advancing RNA-targeted drug discovery and development. Projecting a vast number of new transformational products on…
In late 2022, Arcturus Therapeutics retained The Chase Group to build out additions to the leadership team. Tasked with identifying the new Chief Medical Officer,…
The Chase Group is pleased to announce the successful recruitment of Elvis Osei Tutu, PharmD, as the Vice President, Head of Regulatory Affairs at Checkmate…
The Chase Group, committed to executive recruitment in life sciences, is pleased to announce the completion of another search for Alexza Pharmaceuticals, successfully securing Mike…